Zobrazeno 1 - 10
of 177
pro vyhledávání: ''
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Dimopoulos, M. A., Špička, I., Quach, H., Oriol, Albert, Hájek, R., Garg, M., Beksac, M., Bringhen, S., Katodritou, E., Chng, W. J., Leleu, X., Iida, S., Mateos, M. V., Morgan, G., Vorog, A., Labotka, R., Wang, B., Palumbo, A., Lonial, S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
© 2020 by American Society of Clinical Oncology.
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
Autor:
Philip Kovoor, Stephen T. Sonis, Kyle Colvett, Jeffrey Mark Brill, Madhur Garg, Neal Dunlap, James Wheeler, Roberto Arevalo-Araujo, Sharon M. Gordon, Francis P. Worden, Abhinand V. Peddada, Matthew Downs, Voichita Bar-Ad, Marcelo Bonomi, Anshu K. Jain, Christopher M. Lee, John M. Buatti, Chaitali Singh Nangia, Carryn M. Anderson, Deborah P. Saunders, Sanford Katz, Jon Holmlund, Amarinthia Curtis, Dukagjin Blakaj, Arielle S. Lee, Sanjiv S. Agarwala, Douglas C. Miller
Publikováno v:
Journal of Clinical Oncology
PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419,
Autor:
Chloe E. Atreya, Tae Won Kim, Elena Elez, Ravit Geva, Hiroki Hara, Tong Dai, Hiroya Taniguchi, Luis A. Diaz, Dung T. Le, Patrick McKay Boland, Rosine Guimbaud, Salah-Eddin Al-Batran, Todd S. Crocenzi, Matthew Burge, Thierry André, Petr Kavan, Dirk Jäger, Eric Van Cutsem, Yi Cui, Takayuki Yoshino, Patricia Marinello, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 1
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 1
Scientia
PURPOSE KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) colorectal cancer (CRC). METHODS This phase II open-labe
Autor:
Daniel L. Price, Ashish V. Chintakuntlawar, Samir H. Patel, Joaquin J. Garcia, Michelle A. Neben-Wittich, Yolanda I. Garces, Daniel J. Ma, Brenda Ginos, Kerry D. Olsen, Darlene E. Graner, Robert L. Foote, Robert C. Miller, Satomi Shiraishi, Kathryn M. Van Abel, Michael L. Hinni, Nathan R. Foster, Katharine A. Price, Jeffrey R. Janus, Mark R. Waddle, Eric J. Moore, Jan L. Kasperbauer
Publikováno v:
Journal of Clinical Oncology. 37:1909-1918
PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain h
Autor:
Daniel M. Geynisman, Rebecca Slack, Lisa Pruitt, Matthew I. Milowsky, W. Kimryn Rathmell, Donna Juarez, Elshad Hasanov, Brian I. Rini, Nizar M. Tannir, Summer Stovall, Troy R. Gilchrist, Elizabeth R. Plimack, Moshe Chaim Ornstein, Eric Jonasch
Publikováno v:
Journal of Clinical Oncology. 36:1588-1593
Purpose Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot
Autor:
Peter Kamper, Alexander Lindholm d'Amore, David W. Scott, Joseph M. Connors, Randy D. Gascoyne, Marcel Nijland, Sohrab P. Shah, Christian Steidl, Anja Mottok, Anke van den Berg, Stephen Hamilton-Dutoit, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Maryse M. Power, Arjan Diepstra, Francesco d'Amore
Publikováno v:
Chan, F C, Mottok, A, Gerrie, A S, Power, M, Nijland, M, Diepstra, A, van den Berg, A, Kamper, P, d'Amore, F, d'Amore, A L, Hamilton-Dutoit, S, Savage, K J, Shah, S P, Connors, J M, Gascoyne, R D, Scott, D W & Steidl, C 2017, ' Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma ', Journal of Clinical Oncology, vol. 35, no. 32, pp. 3722-3733 . https://doi.org/10.1200/JCO.2017.72.7925
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed
Publikováno v:
Journal of Clinical Oncology. 35:3306-3314
Purpose The low-income subsidy (LIS) substantially lowers out-of-pocket costs for qualifying Medicare Part D beneficiaries who receive orally administered chemotherapy. We examined the association of LIS with the use of novel oral immunomodulatory dr
Autor:
Wenjie Zhu, Qiao Li, Shanshan Chen, Ying Fan, Puyuan Xing, Zongbi Yi, Qing Li, Meiying Li, Fei Ma, Jiayu Wang, Binghe Xu, Ruigang Cai, Bo Lan, Yang Luo, Pin Zhang, Peng Yuan
Publikováno v:
Journal of Clinical Oncology. 35:3105-3112
Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)–positiv
Autor:
Maximilian Hochmair, Sang-We Kim, Frank G. Haluska, Edward S. Kim, Luis Paz-Ares Rodríguez, Karen L. Reckamp, Howard West, Egbert F. Smit, William M. Reichmann, David Kerstein, D. Ross Camidge, Rudolf M. Huber, Scott N. Gettinger, Karin Holmskov Hansen, Natasha B. Leighl, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn, Dong Wan Kim, Harry J.M. Groen
Publikováno v:
Kim, D W, Tiseo, M, Ahn, M J, Reckamp, K L, Hansen, K H, Kim, S W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Rodríguez, L G P A, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : A randomized, multicenter phase II trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational